Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 2 days ago

Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best low-priced pharma stocks on this list. TheFly reported on June 23 that TAK announced... Full story

Yahoo Finance • 2 days ago

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candi... Full story

Mentioned:

BMY
MRK
RXRX
SMMT
SNY

Yahoo Finance • 8 days ago

Takeda finalizes 18-month transition: Julie Kim officially appointed President & CEO

Takeda (TAK [https://seekingalpha.com/symbol/TAK]) has completed its 18-month leadership transition. Following a shareholder vote at the company’s 150th annual general meeting of shareholders, the board of directors formally appointed [htt... Full story

Yahoo Finance • 16 days ago

AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus

BCC Research LLC "The Pulse Report highlights AI's growing role in preclinical and translational development as biopharma companies seek competitive advantage in bispecific antibodies." Boston, June 15, 2026 (GLOBE NEWSWIRE) -- Artificia... Full story

Yahoo Finance • 22 days ago

Takeda gets FDA review for Entyvio label expansion in children

[Takeda Pharmaceutical Company. Takeda recently acquired Irish drugmaker Shire I] jetcityimage/iStock Editorial via Getty Images * Takeda (TAK [https://seekingalpha.com/symbol/TAK]) announced that the Food and Drug Administration has ac... Full story

Yahoo Finance • 22 days ago

FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease; PDUFA Set In Q1,2027

(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application or sBLA for intravenous ENTYVIO (vedolizumab) for the treatment of... Full story

Yahoo Finance • last month

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict

Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement to keep market monopoly of its constipation drug Amitiza (lubipr... Full story

Mentioned:

Yahoo Finance • last month

Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion

Company Logo The global hepatic cirrhosis market is expanding rapidly, fueled by increasing liver disease cases, advanced treatment options, and improved healthcare infrastructure. Conditions like hepatitis, alcohol abuse, and metabolic d... Full story

Mentioned:

ABT
BMY
GILD
GSK
NVS

Yahoo Finance • last month

Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial

argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Syst... Full story

Mentioned:

ARGX
CRM
GILD
MRK
NVO
VEEV

Yahoo Finance • 2 months ago

Takeda's Next Wave of Drugs Has Investors Watching Closely

Takeda Pharmaceutical Company Ltd. (NYSE:TAK) reported fourth-quarter sales of $6.98 billion, or 1.094 trillion yen, missing Wall Street estimates of $7.05 billion. The Japanese drugmaker reported adjusted earnings of 28 cents per ADR (89... Full story

Yahoo Finance • 2 months ago

Takeda Pharmaceutical Non-GAAP EPS of ¥517.00, revenue of ¥4505.7B; gives FY2026 forecast

* Takeda Pharmaceutical press release [https://seekingalpha.com/pr/20512619-takeda-announces-fy2025-full-year-results-and-fy2026-outlook-highlighted-by-excellent] (TAK [https://seekingalpha.com/symbol/TAK]): FY Non-GAAP EPS of ¥517.00.... Full story

Yahoo Finance • 2 months ago

Earnings live updates: Plug Power, Hims & Hers set to kick off week of quarterly updates

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations. So far this earnings season, S&P 500 companies have... Full story

EXEL
MRK
NVS
PFE